GKOS

$102.93

Post-MarketAs of Mar 17, 8:00 PM UTC

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$102.93
Potential Upside
5%
Whystock Fair Value$108.08
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.98B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-26.38%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.83

Recent News

Simply Wall St.
Feb 26, 2026

Should Glaukos’ (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors?

In February 2026, Glaukos Corporation reported fourth-quarter 2025 results showing sales of US$143.12 million and a net loss of US$133.66 million, including a US$112.87 million intangible asset impairment, while also filing a US$69.25 million shelf registration for 575,108 common shares related to its employee stock ownership plan and issuing 2026 sales guidance of US$600 million to US$620 million. These updates highlight a company balancing rapid top-line expansion and a deepening product...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Feb 23, 2026

Strong Results with 38.1% Revenue Growth Lifted Glaukos (GKOS) in Q4

Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded here. In the fourth quarter of 2025, the Small Company Fund (Investor shares) fell 1.50%, behind the Russell 2000® Growth index’s 1.22% gain. Real estate and […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Feb 20, 2026

Glaukos Corporation Q4 2025 Earnings Call Summary

Moby summary of Glaukos Corporation's Q4 2025 earnings call

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Feb 19, 2026

Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data

This biotech specializes in clinical-stage therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Feb 19, 2026

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead

Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.